RxDoctor Payments Data

Asif Zia, MD

Internal Medicine · Lillington, NCNPI 1649238353

Payments from drug & device makers

$9,119in general payments, 2019–2025

Across 526 payments — averaging $17.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$2K
  • Gilead$1K
  • Novo Nordisk$1K
  • Merck$537
  • AbbVie$435
  • Lilly USA, LLC$432
  • plus $4K from 41 others

What the payments were for

  • Food & beverage$8,84597%
  • Education$2743%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,119 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$77,333
Medicare patients
279
Services billed
1,325

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
DovatoDolutegravir Sodium/Lamivudine94$275,126
BiktarvyBictegrav/Emtricit/Tenofov Ala35$142,629
OzempicSemaglutide100$99,908
JardianceEmpagliflozin117$96,312
EliquisApixaban81$70,365
Trelegy ElliptaFluticasone/Umeclidin/Vilanter76$55,800
XareltoRivaroxaban65$45,638
Tresiba Flextouch U-200Insulin Degludec72$44,301
JulucaDolutegravir/Rilpivirine12$41,347
RybelsusSemaglutide31$39,916
MounjaroTirzepatide32$36,753
DescovyEmtricitabine/Tenofov Alafenam14$30,372
PifeltroDoravirine12$20,786
JanuviaSitagliptin Phosphate31$19,916
LinzessLinaclotide29$18,978

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyDovato, Juluca$1,969$316,473106 claims
GileadBiktarvy, Descovy$1,125$173,00149 claims
Novo NordiskOzempic, Rybelsus$1,098$139,824131 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$264$115,680144 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$200$72,758114 claims
PfizerEliquis$292$70,36581 claims
MerckPifeltro, Januvia, Janumet$537$51,11563 claims
Johnson & JohnsonXarelto$229$45,63865 claims
Lilly USA, LLCMounjaro$432$36,75332 claims
AbbVieLinzess, Synthroid$435$21,70961 claims
AstraZenecaFarxiga$307$14,89821 claims
NovartisEntresto$77$14,80212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Lillington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →